and is the major cause of anaesthesia-induced death. Malignant hyperthermia susceptibility is usually diagnosed by the in vitro contracture test (IVCT) performed on fresh muscle biopsies exposed to caffeine and halothane, respectively. Around 50% of affected families are linked to the ryanodine receptor (RYR1) gene. The human RYR1 gene maps to chromosome 19q13.1 and encodes a protein that associates as a homotetramer and acts as a calcium-release channel from the sarcoplasmic reticulum. To date, 17 mutations have been identified in the coding region of the RYR1 gene and appear to be associated to the MH-susceptible phenotype. Here we describe a rare case of discordance between genotype (characterised by the presence of the Arg614Cys mutation in the RYR1 gene) and MH-normal typed phenotype. Although the IVCT remains a very reliable procedure for the assessment of MH status, genetic data can provide in some cases an additional aid to clinical diagnosis.
Introduction
Malignant hyperthermia (MH) is an inherited autosomal dominant pharmacogenetic disorder and is the major cause of anaesthesia-induced death. The symptoms of an MH attack, triggered by widely used inhalational anaesthetics and depolarizing muscle relaxants, are muscle rigidity, accelerated metabolism, contractures, hyperthermia and tachycardia. Malignant hyperthermia susceptibility (MHS) can be diagnosed by the in vitro contracture test (IVCT) performed on fresh muscle biopsies exposed to caffeine and halothane, respectively. 1 Malignant hyperthermia has a considerable genetic heterogeneity; only about 50% of affected families are linked to the ryanodine receptor (RYR1) gene. The human RYR1 gene maps to chromosome 19q13.1 and encodes a protein that associates as a homotetramer and acts as a calcium-release channel from the sarcoplasmic reticulum (see Mickelson and Louis 2 for review). To date, 17 mutations have been identified in the coding region of the RYR1 gene. 2, 3 All the mutations appear to be associated to the MHS phenotype, identified by the IVCT, although there are some reports of discordance between genotype and phenotype. [4] [5] [6] [7] [8] Furthermore, other MH loci have been mapped to chromosomes 3q, 7q and 17q 2 and recently to chromosomes 1q and 5p. 9 Regarding the locus on chromosome 1, a mutation in the CACNL1AS gene, which encodes the α1-subunit of the skeletal muscle dihydropyridine receptor, is associated with the MHS phenotype in a large family. 10 Co-segregation of the MHS phenotype with a polymorphic microsatellite DNA marker, adjacent to the gene of the α2/δ-subunit of the dihydropyridine receptor, which maps to chromosome 7q21-22, was reported in one German pedigree. 11 No mutations in this gene have yet been described. Recently, linkage analysis in a family in which both hyperkalemic periodic paralysis and MH were inherited as autosomal-dominant traits, indicates a probable association of MH to the adult skeletal muscle sodium channel (SCN4A) gene on chromosome 17. 12 The candidate genes for the other MH loci have not yet been identified.
Here we report a rare case of discordance between genotype, characterised by the presence of the Arg614Cys mutation in RYR1, and MH-normal typed phenotype, in a family from the South of Italy Malignant Hyperthermia Centre.
Patients and Methods
The family NA-1 was referred to the South of Italy Malignant Hyperthermia Centre because subject 2 of the pedigree (see Figure 1 ), the proband, had a severe MH attack, characterised by generalised muscle rigidity and tachyarrhythmias, during anaesthesia for appendectomy. Seven members of the family underwent the standardised European IVCT; 1 the conditions of muscle fibers were: twitch 2.5-16.6 g, weight 0.15-0.2 g, Discordant genotype/phenotype in malignant hyperthermia t G Fortunato et allength 1.5-2.5 cm. All the tests were performed within 1-3 hours of the biopsy. A force increase of at least 0.2 g following either 2% halothane or 2 mM caffeine is required to score a sample as MHS. Contraction threshold at higher concentrations than these were considered normal. The conditions of the muscle of subject 81 were comparable with all the other subjects of the family and within the limits assigned by the European criteria as indicated above. Individual 81 was never exposed to anaesthetic agents.
DNA was extracted from 10 ml of two independent whole blood samples collected from each subject and screened for the Arg163Cys, Gly341Arg, Arg614Cys, Arg614Leu, Arg2163Cys, Arg2163His, Val2168Met and Gly2435Arg mutations as previously described. [13] [14] [15] [16] [17] The DNA was sequenced by fluorescent dye-terminator cycle sequencing on an automated sequencer (ABI 373A, Applied Division, Perkin Elmer, Foster City, CA, USA). The microsatellite repeat markers for loci D19S191, D19S220, RYR1-CA, D19S422 and D19S223 18 were typed by PCR amplification in a 25 µl reaction volume containing 100 ng of genomic DNA, 0.1 µmol/l of each primer, 0.2 mmol/l dNTPs, 10 mmol/l TrisHCl, pH 8.3 at 25°C, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.001% gelatin (w/v), 1.5 µCi of α 32 P dATP (3000 Ci/mmol) and 0.02 U/µl of Taq polymerase. After 5 min incubation at 95°C, the samples were subjected to 35 cycles of 45 s at 94°C, 45 s at the annealing temperature (42°C for D19S422, 46°C for D19S191, D19S220 and D19S223, 54°C for RYR1-CA) and 45 s at 72°C, followed by a final extension step at 72°C for 5 min. Marker alleles were separated on 4% polyacrylamide sequencing gels, detected by autoradiography and typed as described elsewhere.
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Results and Discussion
Thirteen individuals of the NA-1 family were screened for eight of the most frequent RYR1 mutations (Arg163Cys, Gly341Arg, Arg614Cys, Arg614Leu, Arg2163Cys, Arg2163His, Val2168Met and Gly2435Arg).
Only the Arg614Cys mutation was detected by restriction analysis and segregates with the MHS phenotype (see Figure 1) , identified by the IVCT, in all the tested subjects. Direct DNA sequencing of PCR products from three heterozygous subjects (individuals 2, 20 and 53) and from the homozygous subject 155 confirmed that the loss of the RsaI restriction site was the result of a 1840C→T transition (Arg-Cys amino acid exchange). Mutation Arg614Cys was also detected in individual 81 of the NA-1 family who was negative at the IVCT (Table 1) , and confirmed by direct sequencing of PCR products (Figure 2) . The pedigree was then typed with five polymorphic microsatellite markers of chromosome 19 (D19S191, D19S220, RYR1-CA, D19S422 and D19S223, in genetic order) and unequivocal haplotypes were constructed. The five MHS individuals share haplotype 11-4-1-8-1, not present in the MH-normal (MHN) individual 157. On the contrary, subject 81, MHN according to the IVCT, bears the haplotype found in the MHS subjects of the pedigree studied.
The discordance observed between genotype and phenotype in subject 81 can be explained:
(ii) by inexact phenotypic characterisation, or (iii) by incomplete penetrance of the Arg614Cys mutation.
The presence of the mutation in individual 81 was detected by restriction enzyme analysis and confirmed by direct DNA sequencing of the PCR product on two independent DNA samples collected at different times, thus rendering the first hypothesis highly unlikely. In addition, the presence of the mutation correlates with the presence of a specific chromosome 19q haplotype, which is absent from individuals who do not carry the substitution. As to the second hypothesis, it is noteworthy that the clinical diagnostic parameters of the IVCT were established to privilege diagnostic sensitivity (99%) rather than diagnostic specificity (93.6%). 19 Nevertheless, four cases of patients who were MH-normal according to the IVCT and later had an MH attack, were reported from the same laboratory, 20 although it may be questioned if cases described are truly false negative. In any case, it is not possible to exclude completely inexact phenotype characterisation. Regarding the third hypothesis, it has been demonstrated that the Arg614Cys mutation exerts a functional effect on the ryanodine receptor RYR1. In fact, sarcoplasmic reticulum vesicles from MHS pigs, carrying a mutation corresponding to the human Arg614Cys mutation, have a higher affinity for ryanodine and are more sensitive to the effect of 4-chloro-m-cresol or caffeine on ryanodine binding than are MHN vesicles. 21 Furthermore, the presence of this mutation in the recombinant rabbit RYR1 expressed in transfected COS-7, 22 myoblastic C 2 C 12 23 or HEK-293 3 cells causes abnormal cytosolic Ca 2 + release in response to the exogenous activators 4-chloro-m-cresol, 22 or caffeine and halothane, 3, 23 respectively. Moreover, there was a close correlation between the results of cellular Ca 2 + photometry and of clinical IVCT used to evaluate the caffeine sensitivity of different RYR1 mutants. 3 Taken together these considerations seem to preclude an incomplete penetrance of the mutation, although it cannot be ruled out that additional mutations in RYR1 or in other MH loci may modify the phenotypic effect of RYR1 mutations in MH families.
Some cases of discordance between genotype and phenotype have been described [4] [5] [6] [7] [8] and they mainly concern discrepancies between MHS IVCT results and the absence of the mutation. [4] [5] [6] 8 The only other instance of an MHN individual bearing the Arg614Cys mutation was reported by Deufel et al. 7 The authors suggested that their results may challenge the causative role of this mutation. Since then there is increasing evidence 3, 21 that the Arg614Cys substitution results in altered functionality of the RYR1 protein. Moreover, Tong et al 3 proposed that once a mutation has been shown in vitro to confer a higher sensitivity than the wild type to the Ca 2 + -releasing effects of caffeine and halothane, the individual carrying such a mutation should be considered MH-susceptible. In conclusion, also on the basis of the foregoing observations, although typed MHN, subject 81 should be regarded as MHS for clinical purposes, since she bears the mutation, and has a high risk familial haplotype. The case described here reinforces the notion that genetic data for MH status can in some cases provide additional diagnostic information, although obviously it cannot replace the IVCT.
